Anti-MET antibodies and compositions
The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
1. An antibody composition comprising a first anti-MET antibody or an antigen-binding portion thereof and a second anti-MET antibody or an antigen-binding portion thereof, wherein:
a) said first anti-MET antibody or antigen-binding portion thereof has heavy chain (H)-CDR1-3 and light chain (L)-CDR1-3 comprising the amino acid sequences of SEQ ID NOs: 21, 22, 23, 24, 25, and 26, respectively; and
b) said second anti-MET antibody or antigen-binding portion thereof has H-CDR1-3 and L-CDR1-3 comprising the amino acid sequences of SEQ ID NOs: 27, 28, 29, 30, 31, and 32, respectively.
2. The antibody composition of claim 1 , wherein said first anti-MET antibody has a heavy chain variable domain (VH) and a light chain variable domain (VL) that comprise the amino acid sequences of SEQ ID NOs: 6 and 8, respectively, and said second anti-MET antibody has a VH and a VL that comprise the amino acid sequences of SEQ ID NOs: 10 and 12, respectively.
3. An antibody composition comprising a first anti-MET antibody and a second anti-MET antibody, wherein:
said first anti-MET antibody has a heavy chain (HC) and a light chain (LC) that comprise the amino acid sequences of SEQ ID NOs: 34 and 33, respectively, and
said second anti-MET antibody has an HC and an LC that comprise the amino acid sequences of SEQ ID NO: 36 and 35, respectively.
4. The antibody composition of claim 1 , wherein said composition has at least one property selected from the group consisting of:
a) induces degradation of MET;
b) inhibits growth in vitro of at least one cell line selected from SNU5, EBC1, MKN45, KatoII, OE33, and Okajima;
c) inhibits MET phosphorylation;
d) inhibits MET downstream signaling;
e) inhibits primary endothelial cell proliferation in the presence or absence of HGF; and
f) inhibits tumor growth in vivo.
5. The antibody composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
6. An anti-MET antibody or an antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof has heavy chain (H)-CDR1-3 and light chain (L)-CDR1-3 that comprise the amino acid sequences of SEQ ID NOs: 21, 22, 23, 24, 25, and 26, respectively.
7. The anti-MET antibody of claim 6 , wherein said antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 34 and a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 33.
8. The anti-MET antibody or antigen-binding portion of claim 6 , wherein said antibody has at least one property selected from the group consisting of:
a) does not bind to mouse or chicken MET;
b) binds to an epitope of human MET comprising residues that are present on the SEMA domain;
c) induces degradation of MET;
d) binds to human MET with a K D of 1×10 −9 M or less;
e) inhibits growth in vitro of at least one cell line selected from SNU5, EBC1, MKN45, KatoII, OE33, and Okajima;
f) inhibits MET phosphorylation;
g) inhibits MET downstream signaling;
h) inhibits primary endothelial cell proliferation in the presence or absence of HGF; and
i) inhibits tumor growth in vivo.
9. A pharmaceutical composition comprising the anti-MET antibody or antigen-binding portion of claim 6 and a pharmaceutically acceptable excipient.
10. A bispecific binding molecule having an antigen-binding domain of a first anti-MET antibody and an antigen-binding domain of a second anti-M ET antibody, wherein:
a) said antigen-binding domain of the first anti-MET antibody has heavy chain (H)-CDR1-3 and light chain (L)-CDR1-3 comprising the amino acid sequences of SEQ ID NOs: 21, 22, 23, 24, 25, and 26, respectively; and
b) said antigen-binding domain of the second anti-MET antibody has H-CDR1-3 and L-CDR1-3 comprising the amino acid sequences of SEQ ID NOs: 27, 28, 29, 30, 31, and 32, respectively.
11. The anti-MET antibody or antigen-binding portion of claim 6 , wherein said antibody has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 6 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.
12. The anti-MET antibody or antigen-binding portion of claim 6 , wherein said antibody has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 16.
13. An anti-MET antibody or an antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof has heavy chain (H)-CDR1-3 and light chain (L)-CDR1-3 that comprise the amino acid sequences of SEQ ID NOs: 27, 28, 29, 30, 31, and 32, respectively.
14. The anti-MET antibody or antigen-binding portion of claim 13 , wherein said antibody has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 12.
15. The anti-MET antibody or antigen-binding portion of claim 13 , wherein said antibody has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 18 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 20.
16. The anti-MET antibody of claim 13 , wherein said antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 36 and a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 35.
17. The anti-MET antibody or antigen-binding portion of claim 13 , wherein said antibody has at least one property selected from the group consisting of:
a) does not bind to mouse or chicken MET;
b) binds to an epitope of human MET comprising residues that are present on the SEMA domain;
c) induces degradation of MET;
d) binds to human MET with a K D of 1×10 −9 M or less;
e) inhibits growth in vitro of at least one cell line selected from SNU5, EBC1, MKN45, KatoII, OE33, and Okajima;
f) inhibits MET phosphorylation;
g) inhibits MET downstream signaling;
h) inhibits primary endothelial cell proliferation in the presence or absence of HGF; and
i) inhibits tumor growth in vivo.
18. A pharmaceutical composition comprising the anti-MET antibody or antigen-binding portion of claim 13 and a pharmaceutically acceptable excipient.
19. The antibody composition of claim 1 , wherein said first anti-MET antibody has a heavy chain variable domain (VH) and a light chain variable domain (VL) that comprise the amino acid sequences of SEQ ID NOs: 14 and 16, respectively, and said second anti-MET antibody has a VH and a VL that comprise the amino acid sequences of SEQ ID NOs: 18 and 20, respectively.
20. A method for treating a patient with a MET-expressing cancer, comprising administering to said patient the antibody composition of claim 1 .
21. A method for treating a patient with a MET-expressing cancer, comprising administering to said patient the anti-MET antibody or antigen-binding portion of claim 6 .
22. A method for treating a patient with a MET-expressing cancer, comprising administering to said patient the bispecific binding molecule of claim 10 .
23. A method for treating a patient with a MET-expressing cancer, comprising administering to said patient the anti-MET antibody or antigen-binding portion of claim 13 .